Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?Maximilian Huttasch, S. Kahl, Michael Roden|Metabolism|2024Cited by 137
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitisIkki Sakuma, Gerald I. Shulman, Mateus T. Guerra et al.|Proceedings of the National Academy of Sciences|2025Cited by 33
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetesNina Saatmann, Martin Schön, Oana‐Patricia Zaharia et al.|Liver International|2023Cited by 8
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitisIkki Sakuma, Gerald I. Shulman, Rafael Calais Gaspar et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Die postprandiale GLP-1- und GIP-Sekretion ist bei kürzlich diagnostiziertem Typ-2-Diabetes reduziert, aber bei steatotischer Lebererkrankung erhöhtMaximilian Huttasch, Michael Roden, Róbert Wágner et al.|Diabetologie und Stoffwechsel|2025Cited by 0